Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD | Market Cap | 67.34M +37.4% |
| Revenue (ttm) | 16.28M +4,823.5% |
| Net Income | -46.58M |
| EPS | -0.02 |
| Shares Out | 3.54B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,017 |
| Average Volume | 1,578,723 |
| Open | 0.0200 |
| Previous Close | 0.0190 |
| Day's Range | 0.0190 - 0.0200 |
| 52-Week Range | 0.0170 - 0.0400 |
| Beta | 0.78 |
| RSI | 43.16 |
| Earnings Date | May 28, 2026 |
About Radiopharm Theranostics
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung the... [Read more]
Financial Performance
In fiscal year 2025, Radiopharm Theranostics's revenue was 12.51 million, an increase of 538.86% compared to the previous year's 1.96 million. Losses were -38.34 million, -20.04% less than in 2024.
Financial StatementsNews
Radiopharm Theranostics Reports Business Update
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (t...
Radiopharm announces new data from Phase 0/1 HEAT trial
Radiopharm (RADX) Theranostics announced that new data from the ongoing Phase 0/1 HEAT trial, evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, will be presented as ...
Radiopharm gets DSMC recommendation to advance 177Lu-RAD202 to next dose
Radiopharm (RADX) announced that it has received a recommendation from the Data Safety and Monitoring Committee, or DSMC, to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the nex...
Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101
(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Tuesday it has signed a supply agreement with Siemens Healthineers for RAD101, a novel imaging small molecule targeting fatty acid synthase (FASN) ...
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Radiopharm Theranostics (RADX), 2566.66% surge in interes...
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinica...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Radiopharm Theranostics (RADX), 2,318.18% surge in intere...
Radiopharm Theranostics Transcript: Study result
Interim phase II-B results for RAD101 in brain metastases show 90% of patients achieving the primary endpoint, with PET imaging providing clear diagnostic value over MRI, especially in equivocal cases. The study is nearing completion, with phase III preparations underway and strong commercial interest reported.
Radiopharm Theranostics Transcript: NWR Virtual Healthcare Conference
RAD101 phase II-B interim results showed strong efficacy in brain metastasis, with final data due by mid-year and phase III planning underway. Multiple first-in-class clinical programs are advancing, with key readouts for RAD204 and RAD202 expected by year-end.
Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
RAD 101 is Radiopharm's novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid...
Radiopharm doses first patient in Phase 1/2a study of BetaBart
Radiopharm (RADX) Theranostics announced the dosing of the first patient in its First-In-Human, FIH, Phase 1/2a clinical trial of 177Lu-Betabart. The Phase 1/2a clinical trial is a dose escalation and
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases
Radiopharm Theranostics Transcript: Emerging Growth Conference 89
Radiopharm Theranostics presented its clinical-stage pipeline, highlighting first-in-class radiopharmaceuticals for brain metastasis and solid tumors, with key milestones and data expected by 2026. Strategic partnerships and a strong supply chain support its differentiated, therapeutics-focused approach.
Radiopharm increases ownership in Radiopharm Ventures to 87.5%
Radiopharm (RADX) Theranostics has increased its ownership stake in Radiopharm Ventures, a joint venture created with The University of Texas MD Anderson Cancer Center, from 75% to 87.5%. Radiopharm’s...
RAD Increases Ownership in Radiopharm Ventures to 87.5%
SYDNEY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative on...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Radiopharm (RADX), 17,700.84% surge in interest AIM Immun...
Radiopharm price target raised to $15 from $12 at Maxim
Maxim analyst Michael Okunewitch raised the firm’s price target on Radiopharm (RADX) to $15 from $12 and keeps a Buy rating on the shares. The firm cites the company having
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Radiopharm (RADX), 22,972.36% surge in interest Pipeline ...
Radiopharm price target raised to $16 from $13 at B. Riley
B. Riley raised the firm’s price target on Radiopharm (RADX) to $16 from $13 and keeps a Buy rating on the shares. Radiopharm reported positive interim Phase 2b imaging data
Radiopharm Theranostics Transcript: Study Update
Interim Phase IIb results show that PET imaging with RAD-101 effectively distinguishes active brain metastases from treatment effects, correlates with patient prognosis, and addresses a major unmet need in post-radiosurgery management. The study is progressing well, with a Phase III trial planned and strong market potential projected.
Why Is Radiopharm Theranostics Stock Rallying Over 140%?
Radiopharm Theranostics Limited (NASDAQ: RADX) stock is trading higher on Monday, with a session volume of 21.33 million compared to the average volume of 26.81 thousand, as per data from Benzinga Pro...
Why Is Radiopharm Theranostics Stock (RADX) Up Today?
Radiopharm Theranostics stock soared on Monday after the company posted results from a clinical trial.
Radiopharm achieves primary endpoint in 92% of patients in RAD 101 trial
Radiopharm (RADX) Theranostics announced interim data from the first twelve patients in its U.S. Phase 2b clinical imaging trial of RAD 101 in brain metastases. RAD 101 is Radiopharm’s novel,
Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent b...